Summit Therapeutics partners with ECOG‑ACRIN on registration‑enabling Phase II/III biliary tract cancer trial
Summit Therapeutics Inc. announced a collaboration with the ECOG‑ACRIN Cancer Research Group to launch the registration‑enabling Phase II/III study EA2251 (NCT07765433) in advanced biliary tract cancer. The open‑label trial will randomize U.S. patients to receive ivonescimab plus gemcitabine and cisplatin versus pembrolizumab or durvalumab plus the same chemotherapy backbone, with overall survival as the primary endpoint. Site activations in the United States are slated to begin in the fourth quarter of 2026, marking the seventh international registrational trial for ivonescimab.
Why it matters
The trial could provide the data needed for regulatory approval of ivonescimab in a high‑unmet‑need cancer, potentially generating future revenue for Summit if the study shows survival benefit.
Key facts
- 1The study is named EA2251 (NCT07765433). finanznachrichten.de
- 2Site activations in the United States are expected to begin in Q4 2026. finanznachrichten.de
- 3The trial will compare ivonescimab plus gemcitabine and cisplatin with pembrolizumab or durvalumab plus gemcitabine and cisplatin. finanznachrichten.de
- 4Overall survival is the primary endpoint. finanznachrichten.de
- 5This is the seventh international registrational Phase II/III trial for ivonescimab. prnewswire.com
- 6Lead investigator is Dr. Deirdre J. Cohen, MD, MS. prnewswire.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.